BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29589441)

  • 1. Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
    Sellmer A; Stangl H; Beyer M; Grünstein E; Leonhardt M; Pongratz H; Eichhorn E; Elz S; Striegl B; Jenei-Lanzl Z; Dove S; Straub RH; Krämer OH; Mahboobi S
    J Med Chem; 2018 Apr; 61(8):3454-3477. PubMed ID: 29589441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
    Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
    Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.
    Lin HS; Hu CY; Chan HY; Liew YY; Huang HP; Lepescheux L; Bastianelli E; Baron R; Rawadi G; Clément-Lacroix P
    Br J Pharmacol; 2007 Apr; 150(7):862-72. PubMed ID: 17325656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis.
    Cantley MD; Fairlie DP; Bartold PM; Marino V; Gupta PK; Haynes DR
    Rheumatology (Oxford); 2015 Sep; 54(9):1713-23. PubMed ID: 25832610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantioselective synthesis and biological investigation of tetrahydro-β-carboline-based HDAC6 inhibitors with improved solubility.
    Grünstein E; Sellmer A; Mahboobi S
    Arch Pharm (Weinheim); 2019 Jun; 352(6):e1900026. PubMed ID: 31056792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
    Oh BR; Suh DH; Bae D; Ha N; Choi YI; Yoo HJ; Park JK; Lee EY; Lee EB; Song YW
    Arthritis Res Ther; 2017 Jul; 19(1):154. PubMed ID: 28673326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009.
    Hsieh IN; Liou JP; Lee HY; Lai MJ; Li YH; Yang CR
    Cell Death Dis; 2014 Apr; 5(4):e1166. PubMed ID: 24722291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
    Géraldy M; Morgen M; Sehr P; Steimbach RR; Moi D; Ridinger J; Oehme I; Witt O; Malz M; Nogueira MS; Koch O; Gunkel N; Miller AK
    J Med Chem; 2019 May; 62(9):4426-4443. PubMed ID: 30964290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
    Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
    Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
    Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
    ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
    Ibrahim HS; Abdelsalam M; Zeyn Y; Zessin M; Mustafa AM; Fischer MA; Zeyen P; Sun P; Bülbül EF; Vecchio A; Erdmann F; Schmidt M; Robaa D; Barinka C; Romier C; Schutkowski M; Krämer OH; Sippl W
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
    Zhou M; Ning C; Liu R; He Y; Yu N
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
    Ling Y; Xu C; Luo L; Cao J; Feng J; Xue Y; Zhu Q; Ju C; Li F; Zhang Y; Zhang Y; Ling X
    J Med Chem; 2015 Dec; 58(23):9214-27. PubMed ID: 26555243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
    Raji I; Ahluwalia K; Oyelere AK
    Bioorg Med Chem Lett; 2017 Feb; 27(4):744-749. PubMed ID: 28131715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.